PMAM
FOLD

Picton Mahoney Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Picton Mahoney Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.2M Buy
1,330,842
+715,674
+116% +$10.3M 0.14% 129
2025
Q4 		$8.76M Buy
+615,168
New +$6.04M 0.07% 232

Other funds holding FOLD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Picton Mahoney Asset Management's FOLD Position: Q1 2026 in Review

Picton Mahoney Asset Management increased its Amicus Therapeutics (FOLD) stake by 116% in Q1 2026, buying an estimated $10.3M and bringing the position to 1,330,842 shares worth $19.2M. The position accounts for 0.14% of the portfolio, ranked #129.

Picton Mahoney Asset Management first reported a position in FOLD in Q4 2025 and has held it in 2 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Picton Mahoney Asset Management held 1,330,842 shares of Amicus Therapeutics worth $19.2M as of Q1 2026.
  • Picton Mahoney Asset Management bought 715,674 Amicus Therapeutics shares in Q1 2026, an estimated $10.3M.
  • Amicus Therapeutics made up 0.14% of Picton Mahoney Asset Management's portfolio in Q1 2026, its #129 holding.
  • Picton Mahoney Asset Management first reported a position in Amicus Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Picton Mahoney Asset Management's 13F filing for Q1 2026, filed 13 May 2026.